Skip to content

Alnylam Pharmaceuticals

US · ALNY #627 by market cap Listed 1970
143.82 -4.00 -2.71%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions decreased by 3 in the most recent period (2026/Q4).
  • Total institutional ownership (as a % of shares) was little changed.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
104.22% -0.09pp
Institutions
950 -3
As of
2026/Q4 vs. prior period

Holder types

Mutual Fund91.35%
Hedge Fund4.50%
Public Company3.56%
Sovereign Wealth Fund1.77%
Government Pension Fund1.52%
Private Company0.84%
VC/PE Fund0.26%
Insurance Company0.20%
Individual/Insider0.18%

Top holders as of 2026-09-30

Capital Research 18.57% · 24.88M sh
FMR 9.00% · 12.05M sh
BlackRock 8.23% · 11.02M sh
T. Rowe Price Group, Inc. 8.03% · 10.76M sh
Vanguard Capital Management, LLC 5.14% · 6.88M sh
Vanguard Portfolio Management, LLC 5.00% · 6.70M sh
Baillie Gifford 4.10% · 5.49M sh
State Street Global Advisors 2.85% · 3.82M sh
Wellington Management Group 2.60% · 3.48M sh
Geode Capital Management, LLC 1.93% · 2.59M sh
Invesco Capital Management LLC 2.59% · 3.47M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 31 buys · 17 sells

NameRoleStake
Phillip Sharp Co-Founder, Member of the Scientific Advisory Board 0.20%
Yvonne Greenstreet Chief Executive Officer 0.04%
Jeffrey Poulton Chief Financial Officer 0.03%
David E. Pyott Independent Director 0.02%
Amy W. Schulman Independent Chairperson 0.02%
Michael Bonney Former Non-Independent Director 0.01%
Tolga Tanguler Former Executive VP & Chief Commercialization Officer 0.01%
Pushkal Garg Executive VP & Chief Research & Development Officer 0.01%
Kevin Fitzgerald Executive VP, Chief Scientific Officer and Head of Early Research & Early Development 0.01%
Melissa McLaughlin Chief Human Resources Officer 0.01%
Bryan Supran Chief Legal Officer 0.01%
Dennis Ausiello Member of the Scientific Advisory Board & Independent Director 0.00%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-09 David E. Pyott Independent Director Derivative Exercise and Retained +3,780 $71.99
2026-11-09 Charles Sigal Independent Director Open Market Acquisition +1,600 $152.25
2026-11-08 Amy W. Schulman Independent Chairperson Open Market Acquisition +1,910 $156.82
2026-10-01 Bryan Supran Chief Legal Officer Open Market Disposition -1,758 $226.88
2026-10-01 Bryan Supran Chief Legal Officer Intent to Sell (Form 144) -1,758 $226.88
2026-09-18 Yvonne Greenstreet Chief Executive Officer Other Acquisition +107 --
2026-05-31 David E. Pyott Independent Director Derivative Exercise and Sale -3,830 $297.71–302.65
2026-05-31 Benjamin Cravatt Director Other Derivative Acquisition +4,393 $295.63
2026-05-19 Peter Kellogg Independent Director Other Acquisition +671 --
2026-05-19 Peter Kellogg Independent Director Other Derivative Acquisition +1,441 $298.48
2026-05-19 David E. Pyott Independent Director Other Acquisition +671 --
2026-05-19 David E. Pyott Independent Director Other Derivative Acquisition +1,441 $298.48
2026-05-19 Charles Sigal Independent Director Other Acquisition +671 --
2026-05-19 Charles Sigal Independent Director Other Derivative Acquisition +1,441 $298.48
2026-05-19 Margaret Hamburg Independent Director Other Acquisition +671 --
2026-05-19 Margaret Hamburg Independent Director Other Derivative Acquisition +1,441 $298.48
2026-05-19 Amy W. Schulman Independent Chairperson Other Acquisition +838 --
2026-05-19 Amy W. Schulman Independent Chairperson Other Derivative Acquisition +1,802 $298.48
2026-05-19 Dennis Ausiello Member of the Scientific Advisory Board & Independent Director Other Acquisition +671 --
2026-05-19 Dennis Ausiello Member of the Scientific Advisory Board & Independent Director Other Derivative Acquisition +1,441 $298.48

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Alnylam Pharmaceuticals discussion 0 comments

Add a comment